This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include Eagle Pharmaceuticals, Cabot, Meritage Homes, Griffon, and APA
by Zacks Equity Research
Eagle Pharmaceuticals, Cabot, Meritage Homes, Griffon, and APA are part of Screen of the Week article.
Press the Buy Button on These 5 High Earnings Yield Picks Now
by Rimmi Singhi
One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.
Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
by Zacks Equity Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
OrganiGram (OGI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Eagle Pharmaceuticals (EGRX) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Eagle Pharmaceuticals (EGRX) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Eagle Pharmaceuticals (EGRX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -2.30% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.
What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?
by Zacks Equity Research
Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.
Philips' (PHG) Q4 Earnings Hit By Supply-Chain Issues, Recall
by Zacks Equity Research
Philips (PHG) fourth-quarter and 2021 results suffer from supply-chain constraints and adverse impact of the Respironics recall.
Zacks.com featured highlights include: Summit Hotel Properties, Meritage Homes, Eagle Pharm and BrightSphere Investment Group
by Zacks Equity Research
Zacks.com featured highlights include: Summit Hotel Properties, Meritage Homes, Eagle Pharm and BrightSphere Investment Group
4 High Earnings Yield Stocks Likely to Pay Off Big Time
by Rimmi Singhi
Summit Hotel (INN), Meritage Homes (MTH), Eagle Pharmaceuticals (EGRX) and BrightSphere (BSIG) could be some attractive bets if you are looking for high earnings yield picks.
Eagle Pharmaceuticals (EGRX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -35.63% and -14.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Teva's (TEVA) Q3 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Teva Pharmaceutical Industries' (TEVA) shares decline after the company misses both earnings and sales estimates for third-quarter 2021. Meanwhile, it reaffirms its 2021 guidance.
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Sep 1, 2021
by Zacks Equity Research
Companies in the news are: NTES, SONN, EGRX, ZEV
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.68% and 1.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up
by Zacks Equity Research
TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.
New Strong Sell Stocks for June 18th
by Zacks Equity Research
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -66.67% and -9.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down
by Zacks Equity Research
TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.